Michele Del Vecchio - Concepedia

Author

Michele Del Vecchio

Fondazione IRCCS Istituto Nazionale dei Tumori ORCID

Also Known As

Del Vecchio, Michele, H. Ahmed, M DELVECCHIO, M Del Vecchio, M R Del Vecchio, M Vecchio, M. D. VECCHIO, M. DEL VECCHIO, M. Del Vecchio, M. DelVecchio

330

Publications

12.4K

Citations

H-Index

Concepts

All Affiliations

Fondazione IRCCS Istituto Nazionale dei Tumori Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Istituti di Ricovero e Cura a Carattere Scientifico Istituto Oncologico Veneto University of Siena

About

Michele Del Vecchio is an author at Fondazione IRCCS Istituto Nazionale dei Tumori specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	48	5.3K
2	Health Sciences	8	8	230
3	Social Sciences	2	2	104
4	Cell Biology	2	2	29
5	Diagnostic Sciences	1	1	14

Michele Del Vecchio

Publications

10.6K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, New England Journal of Medicine	2017	2.1K
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial Michael A. Davies, Philippe Saïag, Caroline Robert, The Lancet Oncology MedicineMelanomaPathologyImmune Checkpoint InhibitorCancer Treatment	2017	759
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, The Lancet Oncology Checkmate 238Surgical OncologyMedicineMelanomaPathology	2020	505
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial Paolo A. Ascierto, Michele Del Vecchio, Caroline Robert, The Lancet Oncology MedicineMelanomaIpilimumab 10Clinical TrialsMetastatic Melanoma	2017	483
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, The Lancet Oncology OncologyBinimetinib Versus DacarbazineMedicineMelanomaPharmacotherapy	2017	482
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab Pier Francesco Ferrucci, Paolo A. Ascierto, Jacopo Pigozzo, Annals of Oncology	2016	389
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Nature Medicine MedicineMelanomaImmune Checkpoint InhibitorOncologyRadiation Oncology	2019	319
Adjuvant chemotherapy with vincristine, cyclophosphamide, and doxorubicin after radiotherapy in local-regional nasopharyngeal cancer: results of a 4-year multicenter randomized study. Annick Rossi, Roberto Molinari, Patrizia Boracchi, Journal of Clinical Oncology Local-regional Nasopharyngeal CancerAdjuvant ChemotherapyPathologyPharmacotherapyRadiation Medicine	1988	289
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study James Larkin, Michele Del Vecchio, Paolo A. Ascierto, The Lancet Oncology MedicineMelanomaSafety StudyPathologyMetastatic Melanoma	2014	289
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated <i>BRAF</i>-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial Paolo A. Ascierto, Mario Mandalà, Pier Francesco Ferrucci, Journal of Clinical Oncology	2022	208

Page 1